---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-000832"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:23:28.674877+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology receives FDA IND clearance for SC291 allogeneic CAR T therapy in B-cell malignancies

## Summary
- FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.
- Goal to report initial SC291 clinical data in 2023; second IND for SC262 (CD22-targeted) expected this year.
- Hypoimmune platform disrupts MHC class I/II expression and overexpresses CD47 to evade immune rejection.
- Preclinical data shown across models; platform also being developed for pancreatic islet cell therapy in type 1 diabetes.

## SEC filing metadata
- accession: 0001564590-23-000832
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459023000832/0001564590-23-000832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459023000832/sana-8k_20230126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-000832
- JSON: https://secwatch.observer/filing/0001564590-23-000832.json
- Plain text: https://secwatch.observer/filing/0001564590-23-000832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.